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Background: A blood pressure drop after bevacizumab administration and its 
clinical significance have not been previously reported. 
Methods: Blood pressure data at 0, 90, and 180 min after a total of 162 
bevacizumab administrations in 81 advanced colorectal cancer patients were 
retrospectively investigated.  
Results Twenty-five patients (30%) demonstrated an average temporary drop of 
20 mm Hg or more in systolic blood pressure. We classified these 25 patients as 
group A and the others as group B. Median time to treatment failure (TTF) was 
significantly longer in group A than group B (291 vs. 162 days; P = 0.02). 
Furthermore, the proportion of patients who required intervention with 
antihypertensive drugs during bevacizumab treatment was significantly higher in 
group A than group B (36% vs 4%; P < 0.01).  
Conclusion This study suggests that a temporary blood pressure drop after 
bevacizumab administration could be a predictive marker for bevacizumab 
treatment.  




Bevacizumab is a recombinant humanized monoclonal antibody that binds to 
vascular endothelial growth factor (VEGF) A and is now widely used for the 
treatment of colorectal cancer in combination with other cytotoxic drugs 
(Giantonio et al, 2007; Hurwitz et al, 2004). Hypertension is one of the most 
common adverse effects and its total incidence is reported to be 10–30% (Zhu et 
al, 2007). Therefore, active monitoring of blood pressure is recommended in 
daily clinical practice during bevacizumab treatment (Maitland et al, 2010). In the 
course of this blood pressure monitoring, we have observed that some patients 
experience a temporary blood pressure drop after administration of 
bevacizumab. Moreover, among these patients, we noted one who responded to 
the third-line therapy using bevacizumab after failure of oxaliplatin and irinotecan. 
These observations prompted us to perform the current study to investigate the 
incidence of a drop in blood pressure after bevacizumab administration, and its 
association with the clinical course of patients with advanced colorectal cancer. 
 




Between August 2007 and October 2010, 85 patients with colorectal cancer 
underwent palliative chemotherapy using bevacizumab at Kyoto University 
Hospital. For these patients, we obtained data using both the designated 
database system (CyberOncology®, CyberLaboratory Co. Ltd., Ibaragi, Japan) 
(Matsumoto, 2007) and the hospital’s electronic medical records system on 
blood pressure values at 0 min (before administration), at 90 min and 180 min 
after the initiation of bevacizumab during the first three cycles of bevacizumab 
treatment. We also investigated the status of antihypertensive drug intake before 
and after bevacizumab treatment. Out of the 85 patients, there were 81 for 
whom two or more sets of blood pressure data from the first three cycles were 
available. Therefore, we retrieved data from a total of 162 bevacizumab 
administrations in 81 patients (data from 2 separate administrations per patient). 
The blood pressure value at 180 min was not monitored in 3 patients who 
received capecitabine/bevacizumab, due to the short infusion period of this 
regimen.  
Treatment with bevacizumab  
Bevacizumab was administered in combination with one of the following 
regimens (FOLFIRI, mFOLFOX6, sLV5FU2, XELOX or capecitabine) as 
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previously reported (Fuchs et al, 2007; Kabbinavar et al, 2003; Saltz et al, 2008). 
None of the patients received bevacizumab as monotherapy. The 
first/second/third dose of bevacizumab was infused over 90/60/30 min, 
respectively as previously reported. (Margolin et al, 2001). 
Statistical methods 
Baseline patient characteristics were compared using the 2 test or Fisher`s 
exact test for dichotomous variables or the Mann-Whitney U test for continuous 
variables. Time to treatment failure (TTF) was defined as the interval between 
the date of initiation and discontinuation of treatment and estimated by the 
Kaplan-Meier method. Patients not experiencing an event were censored at the 
last follow-up visit. Comparisons of the time-to-event distributions were made 
using the log rank test, with the hazard ratio (HR) and its 95% confidence 
intervals (CI) calculated from a Cox regression model. All P values are two-sided. 







Patient baseline characteristics are summarized in Table 1. Sixteen patients 
(20%) had received antihypertensive drugs before the first date of bevacizumab 
treatment and 11 patients (14%) required intervention with anti-hypertensive 
drugs during bevacizumab treatment. 
Blood pressure changes after bevacizumab administration 
Figure 1 shows a waterfall plot analysis of the change in systolic blood pressure. 
The proportion of patients experiencing a blood pressure drop was greater than 
those showing a blood pressure elevation between 0 and 90 min (Figure 1A and 
1B), and this proportion was reversed between 90 and 180 min (Figure 1C and 
1D). A total of 25 patients (30%) demonstrated a temporary drop of 20 mm Hg or 
more on average and we classified these patients as group A and the others as 
group B. Patient characteristics of group A and group B are summarized in Table 
1, and there were no significant differences between the 2 groups in their 
baseline characteristics. Systolic blood pressure (mean±SD) at 0, 90, and 180 
min is shown in Figure 2. In group A the mean blood pressure drop between 0 
and 90 min was 25 and 30 mm Hg in the first and second monitoring, 
respectively, compared with 3 and 5 mm Hg in group B. Thus, similar trends 
were observed through two separate cycles in each group. 
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Association between temporary blood pressure drop and TTF 
We then compared TTF between group A and group B. TTF was significantly 
longer in group A (291 days; 95% CI, 266-316 days) compared to group B (162 
days; 95% CI, 122-202 days) with a HR of 0.53 (95% CI, 0.31 – 0.89; P = 0.02) 
(Figure 3).  
 
Discussion 
Since hypertension associated with bevacizumab treatment has been well 
documented (Hurwitz et al, 2004; Zhu et al, 2007), many physicians pay 
attention to this phenomenon, whereas a blood pressure drop is likely to be 
overlooked. In this study, 25 patients (30%) experienced a temporary systolic 
blood pressure drop of 20 mm Hg or more after bevacizumab administration. We 
consider this observation not to be a result of chance, physiological variability or 
inaccurate measurement for the following reasons. 
Firstly, the drop in blood pressure was a temporary phenomenon and blood 
pressure returned to baseline levels between 90-180 min after bevacizumab 
administration (Figures 1 and 2). If this drop was the result of a resolution of prior 
blood pressure elevation due to the white-coat effect or pre-injection anxiety, 
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then the reduced blood pressure at 90 min would be more likely to remain at this 
lower level until 180 min.  
Secondly, this phenomenon was observed through two separate cycles.  
Thirdly, in the first cycle bevacizumab was infused over 90 min and no other 
drugs were infused until 90 min.  
Out of the 25 patients classified as group A, 10 received anti-epidermal growth 
factor receptor (EGFR) monoclonal antibody and blood pressure was monitored 
at 0 min and 60 min after the administration of this antibody during the first cycle. 
Mean change in systolic blood pressure were 3 mmHg, and no patients 
demonstrated a blood pressure drop of 20 mmHg or more. These results also 
support the idea that a blood pressure drop after bevacizumab administration 
was not merely caused by a result of chance, physiological variability or 
inaccuracy of blood pressure measurement. 
In line with our current results, Iqbal et al (2007) reported the case of a patient 
with colorectal cancer who developed bevacizumab-associated hypotension.  
We speculate that more similar but unreported cases exist in daily clinical 
practice.  
Next, we investigated the association between this phenomenon and TTF 
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because recent studies have suggested a positive correlation between 
hypertension after bevacizumab treatment and clinical outcome (Dahlberg et al, 
2010; De Stefano et al, 2011; Scartozzi et al, 2009). Even after adjustment for 
treatment line and regimen, the results show a significantly longer TTF in group 
A than in group B (P = 0.02; Figure 3). Furthermore, the proportion of patients 
who required intervention with antihypertensive drugs during bevacizumab 
treatment was significantly higher in group A compared to group B (36% vs 4%; 
P < 0.01; Table 1), which supports previous studies demonstrating that 
bevacizumab-related hypertension was positively associated with clinical 
outcome. Our study is limited because it is a retrospective analysis of a small 
sample, including various treatment lines and regimens. However, a designated 
database system (CyberOncology®) enables us to record TTF at the time an 
event occurs (Matsumoto, 2007), and we believe this system has contributed 
to improving the accuracy of the current data. In fact, TTF of patients who 
received bevacizumab as first-line or second-line treatment was 295 days (95% 
CI, 167-421 days) and 199 days (95% CI, 148-249 days), respectively. These 
results are comparable with previous data of progression-free survival (PFS) 
from large prospective clinical trials evaluating the efficacy of bevacizumab in 
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patients with advanced colorectal cancer (Fuchs et al, 2007; Giantonio et al, 
2007; Hurwitz et al, 2005; Saltz et al, 2008).  
In summary, our current study demonstrates that, in some patients, blood 
pressure drops temporarily after bevacizumab administration to varying degrees, 
and that this phenomenon is associated with a longer TTF. Since this 
phenomenon was observed from the first cycle of bevacizumab treatment, it 
could predict the clinical course of treatment at an earlier time point than 
bevacizumab-related hypertension. Future prospective studies with a larger 






This work was supported by the Grant-in-Aid for Young Scientists [grant number 
21790661] from the Japan Society for the Promotion of Science and the 
Japanese Research Foundation for Clinical Pharmacology. 
Conflict of interest 
Research funding: Kazuhiro Yanagihara, Chugai and Taiho.  
 
Abbreviations: 
FOLFIRI; fluorouracil/leucovorin/irinotecan  
mFOLFOX6; fluorouracil/leucovorin/oxaliplatin 
sLV5FU2; fluorouracil/leucovorin 





Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH (2010) Clinical 
course of advanced non-small-cell lung cancer patients experiencing 
hypertension during treatment with bevacizumab in combination with carboplatin 
and paclitaxel on ECOG 4599. J Clin Oncol 28: 949-954 
 
De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S (2011) 
Bevacizumab-related arterial hypertension as a predictive marker in metastatic 
colorectal cancer patients. Cancer Chemother Pharmacol [Epub ahead of print] 
 
Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, Schulz J, 
Richards D, Soufi-Mahjoubi R, Wang B, Barrueco J (2007) Randomized, 
controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in 
first-line treatment of metastatic colorectal cancer: results from the BICC-C 
Study. J Clin Oncol 25: 4779-4786 
 
Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, 
Schwartz MA, Benson AB, 3rd (2007) Bevacizumab in combination with 
13 
 
oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated 
metastatic colorectal cancer: results from the Eastern Cooperative Oncology 
Group Study E3200. J Clin Oncol 25: 1539-1544 
 
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, 
Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, 
Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin 
for metastatic colorectal cancer. N Engl J Med 350: 2335-2342 
 
Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, 
Hambleton J, Novotny WF, Kabbinavar F (2005) Bevacizumab in combination 
with fluorouracil and leucovorin: an active regimen for first-line metastatic 
colorectal cancer. J Clin Oncol 23: 3502-3508 
 
Iqbal K, Chu Q, Mei Q, Chen Y (2007) Bevacizumab-associated reversible 
hypotension. Clin Oncol (R Coll Radiol) 19: 800-801 
 
Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman 
14 
 
G, Griffing S, Bergsland E (2003) Phase II, randomized trial comparing 
bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients 
with metastatic colorectal cancer. J Clin Oncol 21: 60-65 
 
Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, 
Leier CV, Lindenfeld J, Liu G, Remick SC, Steingart R, Tang WH (2010) Initial 
assessment, surveillance, and management of blood pressure in patients 
receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl 
Cancer Inst 102: 596-604 
 
Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, 
Adelman D, Stalter S, Breed J (2001) Phase Ib trial of intravenous recombinant 
humanized monoclonal antibody to vascular endothelial growth factor in 
combination with chemotherapy in patients with advanced cancer: 
pharmacologic and long-term safety data. J Clin Oncol 19: 851-856 
 
Matsumoto SN, T. Kanai, M. et al. (2007) Development of a novel information 
technology (IT) system using the electronic medical record (EMR) in daily clinical 
15 
 
practice (abstract). J Clin Oncol 25 (suppl 18S): 17066 
 
Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, 
Lichinitser M, Yang TS, Rivera F, Couture F, Sirzen F, Cassidy J (2008) 
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line 
therapy in metastatic colorectal cancer: a randomized phase III study. J Clin 
Oncol 26: 2013-2019 
 
Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, 
Cascinu S (2009) Arterial hypertension correlates with clinical outcome in 
colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 20: 
227-230 
 
Zhu X, Wu S, Dahut WL, Parikh CR (2007) Risks of proteinuria and hypertension 
with bevacizumab, an antibody against vascular endothelial growth factor: 


















Figure 1.  
(A) First monitoring 
(B) Second monitoring 















Figure 1.  
(C) First monitoring (D) Second monitoring 
(mm Hg) (mm Hg) 


















0 180 90 
Figure 2.  
(mm Hg) (mm Hg) 
0min 90min 180min 
136±17 111±15 131±17 
0min 90min 180min 
142±15 112±15 127±17 
(C) First monitoring (D) Second monitoring 


















Figure 2.  
(mm Hg) (mm Hg) 
0min 90min 180min 
136±17 111±15 131±17 
0min 90min 180min 
136±17 111±15 131±17 

















P = 0.02 
Figure 3.  
Table 1. Patient characteristics
Characteristic All patients(n = 81 )
Group A
(n = 25 )
Group B
(n = 56) P -value
Gender - no. (%)
Male 42 (52) 9 (36) 33 (59) 0.09
Female 39 (48) 16 (64) 23 (48)
Age (years)
Median 64 64 65 0.93
Range 34–82 42–81 34–82
Primary tumor - no. (%)
Colon 51 (63) 15 (60) 36 (64) 0.71
Rectum 30 (37) 10 (40) 20 (36)
Metastatic site
Liver 48 11 37
Lung 37 13 24
Other 46 17 29
No of sites - no. (%)
One 42 (52) 12 (48) 30 (54) 0.77
More than one 39 (48) 13 (52) 26 (47)
CEA - no. (%)
＜10 ng/ml 27 (33) 8 (32) 19 (34) 0.93
≧10 ng/ml 54 (67) 17 (68) 37 (66)
Treatment line - no. (%)
First line 23 (28) 8 (32) 15 (27) 0.56
Second line 33 (41) 8 (32) 25 (45)
Third line or later 25 (31) 9 (36) 16 (28)
Chemotherapy regimen - no. (%)
FOLFIRI 27 (33) 11 (44) 16 (29) 0.16
mFOLFOX6/XELOX 25/3 (35) 4/1 (20) 23 (41)
sLV5FU2/capecitabine 23/3 (32) 8/1 (36) 17 (30)
Intake of antihypertensive drugs - no. (%)
YES 16 (20) 3 (12) 13 (23) 0.37
Calcium-channel blockers 11 1 10
Angiotensin II receptor blockers 8 2 6
Others 2 0 2
NO 65 (80) 22 (88) 43 (77)
No. of patients requiring intervention with
antihypertensive drugs during
bevacizumab treatment - no. (%)
11 (14) 9 (36) 2 (4) <0.001
